Erlotinib-associated rash in patients with EGFR mutation-positive non-small-cell lung cancer treated in the EURTAC trial

Filippo De Marinis, Alain Vergnenegre, Antonio Passaro, Catherine Dubos-Arvis, Enric Carcereny, Ana Drozdowskyj, Ali Zeaiter, Pablo Perez-Moreno, Rafael Rosell

Research output: Contribution to journalArticlepeer-review

Abstract

Aim: This analysis investigates incidence and time course of rash in the EURTAC study. Materials & methods: Patients with EGFR mutation-positive non-small-cell lung cancer were randomized 1:1 to receive once daily erlotinib or 3-weekly cycles of chemotherapy. Results: Of the 86 erlotinib-treated patients, 71 reported rash. Median time to first rash appearance was 0.7 months. Most patients (n = 65) had the same or lower grade rash at final assessment compared with initial assessment. Of the 21 patients with decreased rash grade between initial and final assessments, 61.9% received no erlotinib dose modification, 42.8% had no concomitant rash treatment. Conclusion: Most rash cases were mild, occurred within 1 month of erlotinib treatment, and rapidly improved without the need for erlotinib dose alterations.

Original languageEnglish
Pages (from-to)421-429
Number of pages9
JournalFuture Oncology
Volume11
Issue number3
DOIs
Publication statusPublished - Feb 1 2015

Keywords

  • EGFR
  • erlotinib
  • non-small-cell lung cancer
  • rash
  • safety

ASJC Scopus subject areas

  • Oncology
  • Cancer Research
  • Medicine(all)

Fingerprint

Dive into the research topics of 'Erlotinib-associated rash in patients with EGFR mutation-positive non-small-cell lung cancer treated in the EURTAC trial'. Together they form a unique fingerprint.

Cite this